University of Washington Propels Seven Innovative Startups


Key Takeaways:

– University of Washington’s spinout facility, CoMotion, has launched seven new startups since July last year.
– The startups’ focus areas range from revolutionary gene therapies to advanced 3D printing technologies.
– CoMotion’s main function is to assist UW researchers in securing patents and launching startups.
– Over the last five years, UW has spun out 52 startups and granted over 2,000 licenses.
– Current active UW spinouts, numbering over 110, employ more than 1,000 people and have collectively raised over $4.1 billion in the last five years.

In a steadfast demonstration of the power of innovation, the University of Washington (UW) has churned out seven promising new startups since July of last year. These budding businesses – hailing from UW’s tech transfer office, CoMotion – cover a broad spectrum of technological advances. The university’s dedication to nurturing entrepreneurial ideas is reflected in the vast array of startups to emerge from its programs, cope with everything from neurological conditions to manufacturing efficiency.

Leveraging Smartphone Technology for Neurological Discovery

One shining example on this illustrious list is Apertur, a startup hailing from Seattle, that harnesses the power of smartphone technology. Apertur is developing a device that gauges pupil response to light, generating vital data to aid in the identification of neurological disorders. Currently seeking FDA approval, the company is in pursuit of research partners in neurodegenerative disease, acute stroke care, and substance use.

Cancer-Fighting Innovations on the Anvil

Another Seattle-based startup, Axxis Bio, is breaking ground in the medical field, developing a revolutionary cancer-fighting drug. Developed in the labs of David Baker and Neil King at UW’s Institute for Protein Design (IPD), the nascent drug is designed to mimic a type of signaling molecule contender to help doctors eliminate cancer cells effectively. The startup is anticipated to secure seed funding in early 2024.

Precision Epigenetic Reprogramming Unveiled

At the cutting edge of molecular biology, Histone Therapeutics is pioneering precision epigenetic reprogramming. The startup’s first breakthrough – a protein that can precisely activate genes – has been licensed through CoMotion and could pave the way for new disease treatment modalities.

The Next Gen in Gene Therapy

Kinea Bio, another Seattle startup, is accelerating the evolution of gene therapies to address neuromuscular diseases. The company recently received funding from PPMD Ventures, assisting in the development of more efficient therapeutic genes.

A New Approach to Duchenne Muscular Dystrophy

An innovator in gene therapy, Myosana’s unique non-viral platform could enhance outcomes and quality of life for patients with significant unmet needs in neuromuscular and cardiac genetic diseases. The first target for this groundbreaking platform is Duchenne muscular dystrophy.

Mapping Biological Tissues with High-resolution DNA Arrays

TopoGene, using a novel application of technologies, is set to revolutionize the field of spatial genomics, facilitating precise mapping of biological tissue. This could have significant implications for analyzing tumor biopsies.

3D Printing for Supply Chain Resilience

Lastly, Polyfos, a startup based in Israel, is making strides in additive manufacturing with a novel 3D printing solution. This first-of-its-kind technology can enhance the efficiency and productivity in the automotive, aerospace, medical sectors and more.

In conclusion, CoMotion continues its journey as a catalyst for innovation, helping UW researchers secure patents and translate their discoveries into actionable businesses. With 52 startups launched in the last five years and over 2,000 licenses granted, the powerhouse shows no signs of slowing down.

Read more

More News